Legal & General Group Plc Makes New $639,000 Investment in iRadimed Corporation $IRMD

Legal & General Group Plc bought a new stake in shares of iRadimed Corporation (NASDAQ:IRMD) in the 2nd quarter, Holdings Channel reports. The firm bought 6,685 shares of the medical equipment provider’s stock, valued at approximately $639,000.

A number of other hedge funds have also recently modified their holdings of the business. Quarry LP purchased a new stake in shares of iRadimed in the third quarter worth approximately $40,000. Tower Research Capital LLC TRC boosted its holdings in iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 495 shares during the period. Global Retirement Partners LLC purchased a new position in iRadimed during the 2nd quarter valued at $84,000. Inspire Investing LLC bought a new position in iRadimed in the 1st quarter valued at $107,000. Finally, Virtus Advisers LLC purchased a new stake in iRadimed in the third quarter worth $117,000. Institutional investors own 92.34% of the company’s stock.

iRadimed Stock Performance

iRadimed stock opened at $84.40 on Wednesday. The company has a 50 day moving average price of $91.77 and a 200-day moving average price of $93.37. iRadimed Corporation has a fifty-two week low of $67.84 and a fifty-two week high of $107.90. The company has a market capitalization of $1.08 billion, a PE ratio of 47.15 and a beta of 0.89.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, topping the consensus estimate of $0.44 by $0.02. The company had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, analysts forecast that iRadimed Corporation will post 1.98 earnings per share for the current year.

iRadimed Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 28th. Stockholders of record on Friday, August 14th were paid a dividend of $0.20 per share. The ex-dividend date was Friday, August 14th. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is currently 44.69%.

Insider Activity at iRadimed

In related news, Director Monty K. Allen sold 1,419 shares of iRadimed stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total value of $122,615.79. Following the completion of the sale, the director directly owned 19,581 shares in the company, valued at $1,691,994.21. The trade was a 6.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 34.60% of the company’s stock.

Analyst Upgrades and Downgrades

IRMD has been the subject of several research analyst reports. Wall Street Zen downgraded iRadimed from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings cut shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.